Page last updated: 2024-10-31

midazolam and Hyaline Membrane Disease

midazolam has been researched along with Hyaline Membrane Disease in 1 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Hyaline Membrane Disease: A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnold, JH1
Truog, RD1
Scavone, JM1
Fenton, T1

Other Studies

1 other study available for midazolam and Hyaline Membrane Disease

ArticleYear
Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion.
    The Journal of pediatrics, 1991, Volume: 119, Issue:4

    Topics: Extracorporeal Membrane Oxygenation; Female; Fentanyl; Humans; Hyaline Membrane Disease; Infant, New

1991